Reckitt Benckiser appoints Cary Claiborne as chief financial officer
Global specialty pharma company Reckitt Benckiser has appointed Cary Claiborne as chief financial officer. He will lead the company’s global financial and information technology operations as of November 10, 2014.
He was selected on the basis of his operational and pharmaceutical experience that the company hopes will drive value creation for shareholders. Prior to this, he was chief financial officer at Sucampo Pharmaceuticals, where he led the worldwide finance, human resources, information technology, investor relations and communications organizations. Mr Claiborne has held senior positions at companies including New Generation Biofuels, Osiris Therapeutics and General Electric.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze